Status:
COMPLETED
Evaluation of Rapid T2-weighted and DWI MR Sequences Reconstructed by Deep Learning for Prostate Imaging
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Conditions:
Prostate Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
MR prostate exam is essential for the diagnosis, workup and follow-up of prostate cancer. It allows to detect subclinical prostate cancer following an increase in the level of PSA. The investigators c...
Eligibility Criteria
Inclusion
- Age ≥ 18 ans
- Healthy subject without history of hepatic disease
- Patient addressed for an prostate MRI
- Ability to give consent
Exclusion
- claustrophobia,
- major obesity (\>140 kg),
- Patient under guardianship or curators
- Age \< 18 years,
- Women,
- History of prostatectomy or irradiation of the prostate
- any contraindication to MRI exam
Key Trial Info
Start Date :
July 28 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2025
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT06094322
Start Date
July 28 2022
End Date
December 1 2025
Last Update
December 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire d'Amiens
Amiens, Picardie, France, 80000